SKTO - my thoughts The Good 1. Vision - this is a
Post# of 36729
Posted On: 10/07/2013 2:45:05 PM
SKTO - my thoughts
The Good
1. Vision - this is a comprehensive one-stop-solution for the MMJ industry, from the strains, to the growers, to the distribution, to the payment, and to the long-term healthcare solution.
2. Effort - seems like management is making an effort to grow the business and acquire assets where they feel they have a gap.
3. Share Structure - at 755M shares this is awesome in OTC land.
4. Intellectual Property - owning strains, owning extraction methods, owning research facilities, all of this translates to intellectual property that can either be used to prevent competition or increase revenues through licensing.
5. Connections - I don't think any other MMJ company has the Hollywood and political connections that SKTO has, which will eventually prove to be quite an advantage.
The Bad
1. Execution - company has done a lot, but they have also NOT done what they had promised, such as the audit (no update), filing for the preferred shares (not dependent on AEGY), filing for the name/CUSIP change (again not dependent on AEGY), and announcing a share dividend without getting the proper documentation in place. That speaks of poor execution.
2. Leadership - you guys might think this is a dream team, but I had a feeling from the start that Allyn is more of a salesman than a chairman. I don't think he's the right person to lead the company - they need an industry insider, one that is trusted by the collectives and dispensaries, not one that is prone to running his mouth.
3. Guilt by Association - the insider history is really hurting the share price; all anyone has to do is google Hipple and they will see the SEC lawsuit. Whether or not Hipple is running the company, and I believe he isn't, the fact the company is linked to Hipple is enough to turn some new investors away. Nothing we can do about it, except to keep proving that Hipple is not part of current SKTO and just part of the dirty past.
The Good
1. Vision - this is a comprehensive one-stop-solution for the MMJ industry, from the strains, to the growers, to the distribution, to the payment, and to the long-term healthcare solution.
2. Effort - seems like management is making an effort to grow the business and acquire assets where they feel they have a gap.
3. Share Structure - at 755M shares this is awesome in OTC land.
4. Intellectual Property - owning strains, owning extraction methods, owning research facilities, all of this translates to intellectual property that can either be used to prevent competition or increase revenues through licensing.
5. Connections - I don't think any other MMJ company has the Hollywood and political connections that SKTO has, which will eventually prove to be quite an advantage.
The Bad
1. Execution - company has done a lot, but they have also NOT done what they had promised, such as the audit (no update), filing for the preferred shares (not dependent on AEGY), filing for the name/CUSIP change (again not dependent on AEGY), and announcing a share dividend without getting the proper documentation in place. That speaks of poor execution.
2. Leadership - you guys might think this is a dream team, but I had a feeling from the start that Allyn is more of a salesman than a chairman. I don't think he's the right person to lead the company - they need an industry insider, one that is trusted by the collectives and dispensaries, not one that is prone to running his mouth.
3. Guilt by Association - the insider history is really hurting the share price; all anyone has to do is google Hipple and they will see the SEC lawsuit. Whether or not Hipple is running the company, and I believe he isn't, the fact the company is linked to Hipple is enough to turn some new investors away. Nothing we can do about it, except to keep proving that Hipple is not part of current SKTO and just part of the dirty past.
(0)
(0)